Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cephalon CLL drug ‘can make a meaningful difference’

Cephalon CLL drug ‘can make a meaningful difference’

4th December 2007

Cephalon has announced that – if approved by regulators – Treanda (bendamustine HCl), its treatment for chronic lymphoctyic leukaemia (CLL), could make a significant difference to patients with the condition.

The firm notes that the drug has had its priority review status accepted by the US Food and Drug Administration (FDA) for its new drug application as a first-line treatment for patients with CLL.

Cephalon filed the application for the compound in September 2007, with the FDA due to make a review decision on the drug by the end of the first quarter of 2008.

Treanda is a purine analogue/alkylator hybrid which preclinical trials have shown kills cancer cells in two ways. The compound damages the DNA in cancer cells leading to apoptosis and also inhibits the division of cancer cells to create new cells.

Dr Lesley Russell, executive vice-president of worldwide medical and regulatory operations, said: “If approved, Treanda will make a meaningful difference as the first new CLL treatment option approved by the FDA since 2001 and could be available as soon as the second quarter of 2008.”

In September 2007, Cephalon reported that it is dedicated to the development of treatments for rare conditions affecting a limited number of patients – known as orphan diseases – such as CLL.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.